Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06439535 + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
PF-06439535 + carboplatin + paclitaxel is a combination therapy consisting of a bevacizumab biosimilar (PF-06439535) and two chemotherapy agents (carboplatin and paclitaxel). This combination is used for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). PF-06439535 is designed to be similar to reference bevacizumab (Avastin), which may stop cancer tumors from growing. The combination was evaluated in a Phase 3 clinical trial (NCT02364999) where it demonstrated similar efficacy and safety to bevacizumab-EU + carboplatin + paclitaxel.
02
Targets
Beyond the preview
Go deeper on PF-06439535 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06439535 + carboplatin + paclitaxel.